title: Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients.
abstract: OBJECTIVE
  Terlipressin decreases portal pressure. However, its effects on variceal pressure have been poorly investigated. This study investigated the variceal, splanchnic and systemic hemodynamic effects of terlipressin.
  
  
  METHODS
  Twenty cirrhotic patients with esophageal varices grade II-III, and portal pressure > or =12 mmHg were studied. Hepatic venous pressure gradient, variceal pressure and systemic hemodynamic parameters were obtained. After baseline measurements, in a double-blind administration, 14 patients received a 2mg/iv injection of terlipressin and six patients received placebo. The same measurements were repeated 60 min later.
  
  
  RESULTS
  No demographic or biochemical differences were observed in basal condition between groups. Terlipressin produced significant decreases in intravariceal pressure from 20.9+4.9 to 16.3+/-4.7 mmHg (p<0.01, -21+/- 16%), variceal pressure gradient from 18.9+/-4.8 to 13.5+/-6.0 mmHg (p<0.01, -28+/-27%), estimated variceal wall tension from 78+/-29 to 59+/-31 mmHg x mm (p<0.01, -27+/-22%), and hepatic venous pressure gradient from 19.4+/-4.5 to 16.8+/-5 mmHg (p<0.01, -14+/-12%) at 60 min. The change in variceal pressure after 60 min of terlipressin administration was greater than the change in wedge hepatic venous pressure (-4.7 mmHg vs -0.5 mmHg, respectively, p<0.0001). Terlipressin also caused significant decreases in heart rate and cardiac index and increases in mean arterial pressure and peripheral vascular resistance.
  
  
  CONCLUSIONS
  Our results demonstrate that terlipressin produces significant and prolonged decreases in variceal pressure and variceal wall tension and has intrinsic effects on portal pressure and systemic hemodynamics. Variceal pressure provides a better assessment of the effects of terlipressin administration on esophageal varices than hepatic venous pressure gradient.
authors.affiliation: Liver Unit, Hospital de Gastroenterologia Dr Bonorino Udaondo, Buenos Aires, Argentina.
authors.forename: G
authors.initials: G
authors.lastname: Romero
authors.forename: D
authors.initials: D
authors.lastname: Kravetz
authors.forename: J
authors.initials: J
authors.lastname: Argonz
authors.forename: M
authors.initials: M
authors.lastname: Bildozola
authors.forename: A
authors.initials: A
authors.lastname: Suarez
authors.forename: R
authors.initials: R
authors.lastname: Terg
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D004311:Double-Blind Method; D004932:Esophageal and Gastric Varices / Q000503:physiopathology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000503:physiopathology*; D008236:Lypressin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011168:Portal System / Q000187:drug effects / Q000503:physiopathology*; D013152:Splanchnic Circulation / Q000187:drug effects; D000077585:Terlipressin
chemical_list: D000959:Antihypertensive Agents; D008236:Lypressin; D000077585:Terlipressin